Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime (RASUNOA-Prime)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02533960
Recruitment Status : Recruiting
First Posted : August 27, 2015
Last Update Posted : October 1, 2019
Sponsor:
Collaborators:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
University of Wuerzburg
Information provided by (Responsible Party):
Prof. Roland Veltkamp, University Hospital Heidelberg

Tracking Information
First Submitted Date August 23, 2015
First Posted Date August 27, 2015
Last Update Posted Date October 1, 2019
Actual Study Start Date June 2015
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: August 26, 2015)
  • Primary hypothesis (ischemic stroke substudy) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of less than 2 weeks" ]
    Intracerebral hemorrhage complications (i.e. sICH, according to NINDS and SITS-MOST)
  • Primary hypothesis (hemorrhagic stroke substudy) [ Time Frame: 24 hours ]
    Proportion of relevant secondary hematoma expansion on follow-up neuroimaging (hematoma expansion of >= 33% or 6 mL)
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
Official Title Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
Brief Summary The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry. It is performed at about 50 certified stroke-units and supported by an unrestricted grant from different pharmaceutical companies to the Heidelberg University Hospital. RASUNOA-Prime is designed to assess the emergency management of acute ischemic and hemorrhagic stroke patients with atrial fibrillation (AF) under different anticoagulation schemes pre stroke: Non-vitamin K antagonist oral anticoagulants (NOAC), Vitamin K antagonists (VKA), and no anticoagulation.
Detailed Description

The main purpose of this observational cohort study is to assess routine emergency management of acute stroke patients with AF under different anticoagulation schemes before the index stroke.

The investigators will address the following aims and objectives:

  1. Describing emergency management of stroke patients (IS and ICH) with AF in clinical routine including early diagnostic, therapeutic and preventive procedures and assessing variations in emergency management of patients with AF by anticoagulation schemes pre stroke.
  2. Identifying variations in risk of early complications (e.g. symptomatic secondary intracerebral haemorrhage in ischemic stroke patients) with AF by different anticoagulation schemes pre stroke.
  3. Determining factors influencing outcome of stroke patients with AF at three months and clarifying the potential influence of different anticoagulation schemes pre stroke.

The registry consists of 2 separate substudies that cover two different patient cohorts: ischemic stroke and intracerebral hemorrhage.

The study will collect information from prospectively enrolling Neurology departments with certified stroke units across Germany.

The principal investigator, Prof. Dr. med. Roland Veltkamp, is affiliated with Imperial College London, UK, and Heidelberg University Hospital, Germany.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population

Acute stroke patients with atrial fibrillation (AF) under different anticoagulation schemes pre stroke [Non-vitamin K antagonists oral anticoagulants (NOAC, also referred to as novel or new oral anticoagulants), Vitamin K antagonists (VKA), and no oral anticoagulation. According to the type of stroke, patients will be enrolled in the ischemic or hemorrhagic stroke substudy.

NOTE: As of 31st of July 2019, enrollment in the ischemic stroke substudy was terminated due to achievement of the targeted enrolling numbers.
Condition
  • Ischemic Stroke
  • Intracerebral Hemorrhage
  • Oral Anticoagulation
  • Cardiovascular Diseases
  • Vascular Diseases
Intervention Other: not applicable (observational study)
Observational study without study related intervention.
Study Groups/Cohorts
  • NOAC

    Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).

    Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).

    Intervention: Other: not applicable (observational study)
  • VKA

    Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).

    Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)

    Intervention: Other: not applicable (observational study)
  • Without OAC

    Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.

    Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation.

    Intervention: Other: not applicable (observational study)
Publications * Haas K, Purrucker JC, Rizos T, Heuschmann PU, Veltkamp R. Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J. 2019 Jun;4(2):181-188. doi: 10.1177/2396987318812644. Epub 2018 Dec 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: August 26, 2015)		 4000
Original Estimated Enrollment Same as current
Estimated Study Completion Date October 2020
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Ischemic stroke substudy:

Inclusion Criteria:

  • Age >= 18 years
  • Informed consent

  • Acute ischemic stroke with either symptoms lasting ≥ 24h or evidence of infarction in brain imaging

    • Anticoagulation with NOAC
    • Anticoagulation with VKA
    • No anticoagulation
  • Previous/present atrial fibrillation

Exclusion Criteria:

  • No informed consent
  • Symptom-onset > 24 h

Hemorrhagic stroke substudy:

Inclusion Criteria:

  • Age >= 18 years
  • Acute primary intracerebral hemorrhage
  • - a) Anticoagulation with NOAC
  • - b) Anticoagulation with VKA
  • - c) No anticoagulation
  • Previous/present atrial fibrillation

Exclusion Criteria:

  • No informed consent
  • Symptom-onset > 24 h
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Roland Veltkamp, Prof. Dr. med. +49 6221 56 ext 38121 r.veltkamp@imperial.ac.uk
Contact: Jan C Purrucker, MD +49 6221 56 ext 6999 jan.purrucker@med.uni-heidelberg.de
Listed Location Countries Germany
Removed Location Countries  
 
Administrative Information
NCT Number NCT02533960
Other Study ID Numbers RASUNOA-Prime
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Prof. Roland Veltkamp, University Hospital Heidelberg
Study Sponsor University Hospital Heidelberg
Collaborators
  • Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo, Inc.
  • University of Wuerzburg
Investigators
Principal Investigator: Roland Veltkamp, Prof. Dr. med. Heidelberg University Hospital, Department of Neurology, Heidelberg, Germany; Department of Stroke Medicine, Imperial College London, London, United Kingdom.
PRS Account University Hospital Heidelberg
Verification Date September 2019